Abstract
Macropinocytosis, a unique endocytosis pathway characterized by nonspecific internalization, has a vital role in the uptake of extracellular substances and antigen presentation. It is known to have dual effects on cancer cells, depending on cancer type and certain microenvironmental conditions. It helps cancer cells survive in nutrient-deficient environments, enhances resistance to anticancer drugs, and promotes invasion and metastasis. Conversely, overexpression of the RAS gene alongside drug treatment can lead to methuosis, a novel mode of cell death. The survival and proliferation of cancer cells is closely related to macropinocytosis in the tumor microenvironment (TME), but identifying how these cells interface with the TME is crucial for creating drugs that can limit cancer progression and metastasis. Substantial progress has been made in recent years on designing anticancer therapies that utilize the effects of macropinocytosis. Both the induction and inhibition of macropinocytosis are useful strategies for combating cancer cells. This article systematically reviews the general mechanisms of macropinocytosis, its specific functions in tumor cells, its occurrence in nontumor cells in the TME, and its application in tumor therapies.
Introduction
Solid tumors frequently outgrow their vascular supply, creating "nutrient deserts" where essential amino acids and glucose are scarce. To survive these harsh conditions, cancer cells often employ macropinocytosis (MP)—a bulk "cell drinking" mechanism. Unlike standard, highly selective endocytosis, MP involves the non-specific, large-scale internalization of extracellular fluid and solids. This review explores how cancer cells exploit this pathway as a metabolic "backdoor" for survival and how researchers are now turning this tactic against the tumor.
The Mechanism of Macropinocytosis
Macropinocytosis is a multi-step process driven by significant actin remodeling. It begins with the formation of membrane ruffles or "cups" that eventually close to form large, fluid-filled vesicles called macropinosomes. These vesicles then undergo a maturation process, often fusing with lysosomes to degrade their contents into usable nutrients.
Key molecular players in this process include Merlin and ezrin, which drive actin remodeling, alongside small GTPases like Rac1 and phosphoinositides (PIs). Mutations in the RAS gene—a common driver in aggressive cancers like pancreatic cancer—are known to significantly upregulate this pathway, allowing cells to scavenge extracellular albumin and collagen to provide a steady supply of glutamine.
A Dual Role: Survival vs. Catastrophe
Macropinocytosis serves as a survival mechanism not only for cancer cells but also for other cells within the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) use MP to survive and subsequently secrete nutrients that support tumor growth. Furthermore, MP contributes to therapeutic resistance; when standard metabolic pathways (like mTOR) are inhibited, cells may ramp up MP to find alternative energy sources.
However, this pathway can also be a "Trojan horse." If over-activated, it leads to methuosis, a non-apoptotic form of cell death. In methuosis, the cell accumulates an excessive number of fluid-filled vacuoles that fail to fuse with lysosomes. This leads to massive cellular swelling and eventual bursting (lysis).
Therapeutic Strategies: Starvation and Induction
Researchers are pursuing two primary avenues for targeting macropinocytosis:
- Inhibition (Starvation): By using compounds like EIPA (a sodium-hydrogen exchange inhibitor) or Bafilomycin A1, clinicians can block the tumor's "emergency" food supply. This strategy is particularly effective when combined with standard chemotherapies to sensitize resistant cells.
- Induction (Methuosis): Several natural products and synthetic drugs are being developed to over-stimulate the pathway. These methuosis inducers force the cell to "drink itself to death" by triggering catastrophic vacuolization.
Challenges and Future Directions
Despite the promise of MP-targeted therapies, several hurdles remain. There is currently a lack of real-time, quantitative methods to monitor macropinocytosis in patients, as researchers still rely on fluorescent markers like dextran. Additionally, many current inhibitors have off-target effects, and because MP occurs in both tumor and immune cells, systemic inhibition might inadvertently dampen the body's natural anti-tumor immune response. Future research must focus on developing more specific, cell-targeted inhibitors and better diagnostic tools to translate these findings into clinical practice.
Summary updated